Epsilon Healthcare Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Epsilon Healthcare's earnings have been declining at an average annual rate of -4.2%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 16.1% per year.
Belangrijke informatie
-4.2%
Groei van de winst
9.1%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 31.2% |
Inkomstengroei | 16.1% |
Rendement op eigen vermogen | -64.7% |
Nettomarge | -82.2% |
Laatste winstupdate | 30 Jun 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Does Epsilon Healthcare (ASX:EPN) Have A Healthy Balance Sheet?
Oct 13Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?
Jun 30We Think Epsilon Healthcare (ASX:EPN) Has A Fair Chunk Of Debt
Sep 26Is Epsilon Healthcare (ASX:EPN) Weighed On By Its Debt Load?
Jun 13Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?
Feb 27Opbrengsten en kosten
Hoe Epsilon Healthcare geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 23 | 7 | -6 | 5 | 0 |
31 Mar 23 | 7 | -10 | 6 | 0 |
31 Dec 22 | 7 | -13 | 6 | 0 |
30 Sep 22 | 6 | -13 | 7 | 0 |
30 Jun 22 | 5 | -13 | 7 | 0 |
31 Mar 22 | 5 | -11 | 8 | 0 |
31 Dec 21 | 5 | -9 | 10 | 0 |
30 Sep 21 | 6 | -9 | 11 | 0 |
30 Jun 21 | 7 | -9 | 12 | 0 |
31 Mar 21 | 7 | -10 | 11 | 0 |
31 Dec 20 | 7 | -11 | 11 | 0 |
30 Sep 20 | 7 | -11 | 11 | 0 |
30 Jun 20 | 6 | -12 | 11 | 0 |
31 Mar 20 | 5 | -12 | 10 | 0 |
31 Dec 19 | 5 | -12 | 10 | 0 |
30 Sep 19 | 4 | -11 | 9 | 0 |
30 Jun 19 | 4 | -11 | 9 | 0 |
31 Mar 19 | 3 | -10 | 9 | 0 |
31 Dec 18 | 3 | -9 | 8 | 0 |
30 Sep 18 | 3 | -7 | 7 | 0 |
30 Jun 18 | 3 | -5 | 6 | 0 |
31 Mar 18 | 2 | -4 | 5 | 0 |
31 Dec 17 | 2 | -3 | 3 | 0 |
Kwaliteitswinsten: EPN is currently unprofitable.
Groeiende winstmarge: EPN is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: EPN is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.
Versnelling van de groei: Unable to compare EPN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: EPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendement op eigen vermogen
Hoge ROE: EPN has a negative Return on Equity (-64.69%), as it is currently unprofitable.